Clovis, Avila to Co-develop Targeted NSCLC Drug with Companion Test in Deal Worth up to $209M

The companies are developing an EGFR mutant-selective inhibitor with a companion diagnostic that will select NSCLC patients with an EGFR mutation linked to resistance to drugs like Iressa and Tarceva.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.